Showing results (1771-1780 of 1,996) with videos related to

Sort By:
Pageof 200
The Lancet. Neurology|July 22, 2006
Neurological aspects of spinal-cord repair: promises and challengesVolker Dietz, Armin Curt
The Lancet. Neurology|July 22, 2006
Psychogenic movement disordersVanessa K Hinson, W Blake Haren
The Lancet. Neurology|November 18, 2006
TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trialC Warren Olanow, Anthony H V Schapira, Peter A LeWitt, et al.
The Lancet. Neurology|December 15, 2006
Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1Sebastien Jacquemont, Randi J Hagerman, Paul J Hagerman, et al.
The Lancet. Neurology|November 15, 2008
Genetic testing for paediatric neurological disordersEnza Maria Valente, Alessandro Ferraris, Bruno Dallapiccola
The Lancet. Neurology|April 7, 2009
Mutations in THAP1 (DYT6) in early-onset dystonia: a genetic screening studySusan B Bressman, Deborah Raymond, Tania Fuchs, et al.
The Lancet. Neurology|April 21, 2009
Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinicZheng Gang Zhang, Michael Chopp
The Lancet. Neurology|February 24, 2009
Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosisBruce D Trapp, Peter K Stys
The Lancet. Neurology|February 10, 2009
Effect of urgent treatment for transient ischaemic attack and minor stroke on disability and hospital costs (EXPRESS study): a prospective population-based sequential comparisonRamon Luengo-Fernandez, Alastair M Gray, Peter M Rothwell
The Lancet. Neurology|August 16, 2008
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging studyBenjamin M Segal, Cris S Constantinescu, Aparna Raychaudhuri, et al.
Pageof 200